country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-P992547

Copy Link Print Information

IBI38D9-L

IBI38D9-L is a human IgG1-type CD79b/CD3 bispecific T-cell engager. IBI38D9-L binds to human CD79b and CD3 with K_d values of 1.45 nM and 119 nM, respectively. IBI38D9-L mediates tumor cell recognition and T-cell engagement, activating T cells and inducing their proliferation and release of cytotoxic molecules. IBI38D9-L exerts T cell-mediated cytotoxicity in a tumor cell-dependent manner, thereby selectively depleting antigen-positive malignant B cells. IBI38D9-L can be used for research on B-cell non-Hodgkin lymphoma.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

IBI38D9-L Chemical Structure

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Species Reactivity
- IC₅₀ & Target
- In Vitro
- In Vivo
- Target
- Conjugated
- Anwendung
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Species Reactivity

Human

IC₅₀ & Target

^[1]

CD79b

1.45 nM (Kd)

CD3

119 nM (Kd)

In Vitro

IBI38D9-L (0.5-80 nM; 180 s) binds human CD79a/b with a K_D of 1.45 nM and human CD3 with a K_D of 119 nM in SPR^[1].
IBI38D9-L (6 h) activates NFAT-luciferase reporter T cells in a CD79b-dependent manner, with EC₅₀ values of 0.034 nM in BJAB, 0.030 nM in Ramos, and 0.13 nM in WSU-DLCL2 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Anti-cancerAdaptive Immunity

Anti-cancer

IBI38D9-L (1-3 mg/kg; days 8-22) significantly inhibited WSU-DLCL2 and Ramos tumor growth in human PBMC-reconstituted NOG mice^[1].
IBI38D9-L (3 mg/kg; single dose) increases tumor-infiltrating CD4⁺ and CD8⁺ T cells and activated T cells in Ramos tumors in humanized NOG mice^[1].

Adaptive Immunity

IBI38D9-L (3-10 mg/kg; days 0, 7, 14, and 21) depleted peripheral B cells and later T cells in human CD34⁺ HSC-engrafted NPG mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

NOG (female, reconstituted with human PBMCs)^[1]
Dosage:

1 mg/kg
Administration:

on days 8, 12, 15, 19, and 22
Result:

Produced a tumor growth inhibition (TGI) of 73% at 1 mg/kg.
No body weight reduction or overt toxicities were observed.

Animal Model:

NOG (female, reconstituted with human PBMCs)^[1]
Dosage:

3 mg/kg
Administration:

on days 6, 9, 13, 16, and 20
Result:

Produced a tumor growth inhibition (TGI) of 62% at 3 mg/kg.
No body weight reduction or overt toxicities were observed.

Animal Model:

NOG (female, reconstituted with human PBMCs)^[1]
Dosage:

3 mg/kg
Administration:

once
Result:

Compared with control, IBI38D9-L increased tumor-infiltrating CD4⁺ and CD8⁺ T cells on both days 1 and 3 after administration.
Activated T cells (CD4⁺CD25⁺ or CD8⁺CD25⁺) were increased in tumor samples from the treated group.
Intracellular granzyme B and perforin within CD4⁺ and CD8⁺ T cells showed similar trends to CD25.
Immunofluorescence confirmed elevated CD3⁺ T cell infiltration in tumors from treated animals.

Animal Model:

HSC-NPG (female, engrafted with human CD34+ hematopoietic stem cells)^[1]
Dosage:

3 mg/kg and 10 mg/kg
Administration:

on days 0, 7, 14, and 21
Result:

Produced a large decrease in B cells in peripheral blood at day 3 after the first dose at 3 and 10 mg/kg, with almost no B cells detected on day 10 and thereafter.
No loss of CD3⁺ T cells was observed at day 3; however, almost no CD3⁺ T cells were detected at day 10 onwards.

Related Protocols :

Target

CD79b & CD3

Conjugated

Unconjugated

Anwendung

ELISA, FACS, Functional assay

Chemical Information

SMILES

[IBI38D9-L]
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Inhibitory Antibodies User Guide (603 KB)

Verweise

[1]. Wang J, et al. Characterization of anti-CD79b/CD3 bispecific antibody, a potential therapy for B cell malignancies. Cancer immunology, immunotherapy : CII. 2023 Feb;72(2):493-507.

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen